The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Risk-adapted therapy: three-day versus five-day oral decitabine in patients with MDS
Yazan Madanat, MD, UT Southwestern Medical Center, Dallas, TX, discusses the findings of a real-world study comparing a three-day oral decitabine regimen to the FDA-approved five-day decitabine regimen in patients with myelodysplastic syndromes (MDS). The majority of patients treated with the three-day regimen were considered low-risk as per IPSS, while those treated with the five-day regimen had a higher blast count (greater than 5%) or higher-risk MDS (HR-MDS). However, when using the newer IPSS-M risk score, there was an equivalent number of patients with HR-MDS in both cohorts. Therefore, some HR-MDS patients could have been undertreated, possibly explaining the shorter survival duration observed with the three-day regimen. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Taiho oncology, Stemline therapeutics, Morphosys, Sierra Oncology, Novartis, OncLive, MD Education, Rigel Pharmaceuticals, Blueprint Medicines; Consultancy: GERON, Blueprint Medicines.
